IPHA
Price
$2.24
Change
+$0.06 (+2.75%)
Updated
Aug 15, 12:28 PM (EDT)
Capitalization
204.48M
33 days until earnings call
MDGL
Price
$365.38
Change
-$5.98 (-1.61%)
Updated
Aug 15, 01:51 PM (EDT)
Capitalization
8.28B
76 days until earnings call
Interact to see
Advertisement

IPHA vs MDGL

Header iconIPHA vs MDGL Comparison
Open Charts IPHA vs MDGLBanner chart's image
Innate Pharma SA
Price$2.24
Change+$0.06 (+2.75%)
Volume$671
Capitalization204.48M
Madrigal Pharmaceuticals
Price$365.38
Change-$5.98 (-1.61%)
Volume$100
Capitalization8.28B
IPHA vs MDGL Comparison Chart in %
Loading...
IPHA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MDGL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
IPHA vs. MDGL commentary
Aug 15, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IPHA is a Hold and MDGL is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 15, 2025
Stock price -- (IPHA: $2.18 vs. MDGL: $371.37)
Brand notoriety: IPHA and MDGL are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: IPHA: 30% vs. MDGL: 89%
Market capitalization -- IPHA: $204.48M vs. MDGL: $8.28B
IPHA [@Biotechnology] is valued at $204.48M. MDGL’s [@Biotechnology] market capitalization is $8.28B. The market cap for tickers in the [@Biotechnology] industry ranges from $100.07B to $0. The average market capitalization across the [@Biotechnology] industry is $1.86B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

IPHA’s FA Score shows that 0 FA rating(s) are green whileMDGL’s FA Score has 1 green FA rating(s).

  • IPHA’s FA Score: 0 green, 5 red.
  • MDGL’s FA Score: 1 green, 4 red.
According to our system of comparison, MDGL is a better buy in the long-term than IPHA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

IPHA’s TA Score shows that 6 TA indicator(s) are bullish while MDGL’s TA Score has 5 bullish TA indicator(s).

  • IPHA’s TA Score: 6 bullish, 4 bearish.
  • MDGL’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, IPHA is a better buy in the short-term than MDGL.

Price Growth

IPHA (@Biotechnology) experienced а +1.67% price change this week, while MDGL (@Biotechnology) price change was +8.50% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +5.55%. For the same industry, the average monthly price growth was +20.96%, and the average quarterly price growth was +20.84%.

Reported Earning Dates

IPHA is expected to report earnings on Sep 17, 2025.

MDGL is expected to report earnings on Oct 30, 2025.

Industries' Descriptions

@Biotechnology (+5.55% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MDGL($8.28B) has a higher market cap than IPHA($204M). MDGL YTD gains are higher at: 20.352 vs. IPHA (18.250).
IPHAMDGLIPHA / MDGL
Capitalization204M8.28B2%
EBITDAN/A-376.15M-
Gain YTD18.25020.35290%
P/E RatioN/AN/A-
RevenueN/A317M-
Total CashN/A843M-
Total DebtN/A120M-
FUNDAMENTALS RATINGS
IPHA vs MDGL: Fundamental Ratings
IPHA
MDGL
OUTLOOK RATING
1..100
2120
VALUATION
overvalued / fair valued / undervalued
1..100
77
Overvalued
65
Fair valued
PROFIT vs RISK RATING
1..100
10033
SMR RATING
1..100
9897
PRICE GROWTH RATING
1..100
4341
P/E GROWTH RATING
1..100
34100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MDGL's Valuation (65) in the Pharmaceuticals Other industry is in the same range as IPHA (77) in the null industry. This means that MDGL’s stock grew similarly to IPHA’s over the last 12 months.

MDGL's Profit vs Risk Rating (33) in the Pharmaceuticals Other industry is significantly better than the same rating for IPHA (100) in the null industry. This means that MDGL’s stock grew significantly faster than IPHA’s over the last 12 months.

MDGL's SMR Rating (97) in the Pharmaceuticals Other industry is in the same range as IPHA (98) in the null industry. This means that MDGL’s stock grew similarly to IPHA’s over the last 12 months.

MDGL's Price Growth Rating (41) in the Pharmaceuticals Other industry is in the same range as IPHA (43) in the null industry. This means that MDGL’s stock grew similarly to IPHA’s over the last 12 months.

IPHA's P/E Growth Rating (34) in the null industry is significantly better than the same rating for MDGL (100) in the Pharmaceuticals Other industry. This means that IPHA’s stock grew significantly faster than MDGL’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
IPHAMDGL
RSI
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
85%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
80%
Bearish Trend 1 day ago
82%
Momentum
ODDS (%)
Bullish Trend 1 day ago
80%
Bullish Trend 1 day ago
80%
MACD
ODDS (%)
Bullish Trend 5 days ago
88%
Bullish Trend 1 day ago
77%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
75%
Bullish Trend 1 day ago
76%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
74%
Bullish Trend 1 day ago
76%
Advances
ODDS (%)
Bullish Trend 10 days ago
72%
Bullish Trend 3 days ago
78%
Declines
ODDS (%)
Bearish Trend 8 days ago
83%
Bearish Trend 19 days ago
80%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
Aroon
ODDS (%)
Bearish Trend 1 day ago
83%
Bullish Trend 1 day ago
60%
View a ticker or compare two or three
Interact to see
Advertisement
IPHA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MDGL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
AIABF0.190.04
+24.00%
CAPITAL A BERHAD
MRTI55.00N/A
N/A
Maxus Realty Trust, Inc.
GLNS0.75N/A
N/A
Golden Star Resource Corp
SLFPF2.72N/A
N/A
ABERDEEN GROUP PLC
HXGBY11.17-0.19
-1.67%
Hexagon AB

IPHA and

Correlation & Price change

A.I.dvisor indicates that over the last year, IPHA has been loosely correlated with MDGL. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if IPHA jumps, then MDGL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IPHA
1D Price
Change %
IPHA100%
-1.55%
MDGL - IPHA
43%
Loosely correlated
-0.56%
SLNO - IPHA
34%
Loosely correlated
-4.66%
VALN - IPHA
30%
Poorly correlated
-6.18%
TNXP - IPHA
29%
Poorly correlated
-3.23%
QSI - IPHA
28%
Poorly correlated
-4.27%
More

MDGL and

Correlation & Price change

A.I.dvisor indicates that over the last year, MDGL has been loosely correlated with ALXO. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if MDGL jumps, then ALXO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MDGL
1D Price
Change %
MDGL100%
-0.56%
ALXO - MDGL
56%
Loosely correlated
-0.85%
NAGE - MDGL
45%
Loosely correlated
-4.05%
IPHA - MDGL
44%
Loosely correlated
-1.55%
RNAC - MDGL
43%
Loosely correlated
-2.39%
GHRS - MDGL
43%
Loosely correlated
+1.71%
More